These drugs are used to treat many breast cancer subtypes, including HER2-positive [14], triple negative [15], hormone receptor-positive [14], and hereditary breast cancers driven by germline mutations in Breast Cancer genes 1 and 2 (BRCA1 and BRCA2) [16]. This evidence concerns the gene ERBB2 and breast cancer.